Sickle Cell Disease Treatment Market Size to Surpass Around USD 8.75 Billion by 2029 | Research Report by Fortune Business Insights
January 09, 2023 05:18 ET | Fortune Business Insights
Pune, India, Jan. 09, 2023 (GLOBE NEWSWIRE) -- The global sickle cell disease treatment market size was valued at USD 1.73 billion in 2021. The market is projected to grow from USD 2.25 billion in...
LOGO roboto color with gray.png
Folia Health Technology Platform Used in First-of-its-Kind Real World Evidence Study for Sickle Cell Disease
September 15, 2022 15:23 ET | Folia Health
BOSTON, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Today, Folia Health announced the initiation of the ASCEND Study, a first-of-its-kind, at-home observational real-world evidence study in which people...
AMR Logo.png
Global Hemoglobinopathies Market is Expected to Reach $7.0 Billion by 2031: Says AMR
August 25, 2022 08:33 ET | Allied Market Research
Portland, OR, Aug. 25, 2022 (GLOBE NEWSWIRE) -- The Global Hemoglobinopathies Market size was estimated at $4.2 billion in 2021 and is expected to hit $7.0 billion by 2031, registering a CAGR of...
Straits Research Pvt Ltd
CRISPR Gene Editing Market Size is projected to reach USD 14.80 Billion by 2030, growing at a CAGR of 29.80%: Straits Research
August 01, 2022 12:40 ET | Straits Research
New York, United States, Aug. 01, 2022 (GLOBE NEWSWIRE) -- CRISPR Gene Editing, also called genome editing, modifies an organism's DNA. This method replaces, adds, or removes genetic material from...
Global Blood and Plasma Components Market
Global Blood and Plasma Components Market Report 2022: A $66.47 Billion Market in 2031 - Increase in Adoption of Business Expansion Strategies in the Market
June 10, 2022 04:48 ET | Research and Markets
Dublin, June 10, 2022 (GLOBE NEWSWIRE) -- The "Blood and Plasma Components Market - A Global and Regional Analysis: Focus on Product, Application, End User and Region - Analysis and Forecast,...
Inserting Hb Variant cartridge
Hemex Health announces breakthrough measurement capability for clinicians monitoring sickle cell disease therapy
May 08, 2022 06:00 ET | Hemex Health
PORTLAND, Ore. and MUMBAI, India, May 08, 2022 (GLOBE NEWSWIRE) -- Hemex Health, a Portland, Oregon-based health-tech startup, announced a significant enhancement to their Gazelle™ Hb Variant test,...
Imara-Logo-Color-RGB.jpg
Imara Announces FDA Clearance of Investigational New Drug Application (IND) for Tovinontrine (IMR-687) for Heart Failure with Preserved Ejection Fraction (HFpEF)
January 25, 2022 07:00 ET | Imara, Inc.
Expanding patient base and potential of Imara’s small molecule oral inhibitor of phosphodiesterase-9 (PDE9) alongside hemoglobin disorders Phase 2 trial aims to select HFpEF patients with enriched...
22157.jpg
Worldwide Hematology Testing Industry to 2027 - by Product, Test Type, End-user and Geography
December 22, 2021 05:18 ET | Research and Markets
Dublin, Dec. 22, 2021 (GLOBE NEWSWIRE) -- The "Hematology Testing Market - Global Outlook & Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering. In-depth Analysis and...
Imara-Logo-Color-RGB.jpg
Imara Presents Clinical and Preclinical Tovinontrine (IMR-687) Data at the American Society of Hematology (ASH) Annual Meeting 2021
December 13, 2021 07:00 ET | Imara, Inc.
BOSTON, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat subjects...
Imara-Logo-Color-RGB.jpg
Imara Announces Primary Endpoint Change in the Ardent Phase 2b Clinical Trial of Tovinontrine (IMR-687) in Sickle Cell Disease
November 22, 2021 07:00 ET | Imara, Inc.
Primary endpoint to be changed to annualized rate of VOCs following written U.S. Food and Drug Administration recommendation No change to conduct or size of trial planned; Ardent trial remains on...